Skip to content

Frontiers in Pharmacology

ISSN 1663-9812

170 papers in the library · 6,125 citations · publishing 2012-2026

Papers

Sort Most recent Most cited

Editorial: Psychoactive natural products: Potential in the treatment of brain diseases and strategies to improve delivery

Frontiers in Pharmacology October 3, 2022 Célia Cabral, Claudia Carbone, Pamela Maher et al.

Psychoactive natural products: Potential in the treatment of brain diseases and strategies to improve delivery For this special issue, focusing on psychoactive natural products with therapeutic potential for the treatment of brain diseases, we have invited authors to contribute with research and review articles illustrating and stimulating the continuing effort in drug discovery and drug...

Buddhist-like opposite diminishing and non-judging during ketamine infusion are associated with antidepressant response: an open-label personalized-dosing study.

Frontiers in Pharmacology July 25, 2022 Kurt Stocker, Matthias Hartmann, Steffen Reissmann et al.

Background: Cognition that is not dominated by thinking in terms of opposites (opposite diminishing) or by making judgments (non-judging) can be found both in Buddhist/mindfulness contexts and in mental states that are fostered by dissociative psychedelics (N-methyl-D-aspartate antagonists) such as ketamine. Especially for the Buddhist/mindfulness case, both opposite diminishing and non-judging...

Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives

Frontiers in Pharmacology July 22, 2022 Leor Roseman, Katrin H. Preller, Evgenia Fotiou et al. 15 citations

The heralded psychedelic renaissance is currently at a new level where psychedelics are being accepted by the scientific community and the public. Medicalization and the ongoing introduction of market forces are imposing a trend in which psychedelic treatments are reduced to focus into strictly pharmacological and psychological effects on the self, rather than interactions with broader social...

Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects

Frontiers in Pharmacology July 13, 2022 Patrick Vizeli, Isabelle Straumann, Urs Duthaler et al. 43 citations

Background: 3,4-Methylenedioxymethamphetamine (MDMA) has shown initial promise as an adjunct in psychotherapy to treat posttraumatic stress disorder (PTSD). Its efficacy and safety have been demonstrated across phase I–III studies. However, the mechanism underlying the potential utility of MDMA to treat PTSD in humans has not yet been thoroughly investigated. Preliminary evidence suggests that...

DOI: 10.3389/fphar.2022.906639 (opens in new tab) Full text (opens in new tab) Fear extinction Skin conductance response Fear-potentiated startle Oxytocin +1

Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant

Frontiers in Pharmacology July 7, 2022 Songbai Xu, Xiaoxiao Yao, Bingjin Li et al. 50 citations

Major depressive disorder (MDD) is a devastating psychiatric disorder which exacts enormous personal and social-economic burdens. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, has been discovered to exert rapid and sustained antidepressant-like actions on MDD patients and animal models. However, the dissociation and psychotomimetic propensities of ketamine have limited its use...

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

Frontiers in Pharmacology June 28, 2022 Nataliya S. Vorobyeva, Alena A. Kozlova 16 citations

Classical psychedelics represent a family of psychoactive substances with structural similarities to serotonin and affinity for serotonin receptors. A growing number of studies have found that psychedelics can be effective in treating various psychiatric conditions, including post-traumatic stress disorder, major depressive disorder, anxiety, and substance use disorders. Mental health disorders...

Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico

Frontiers in Pharmacology June 27, 2022 Snehal Bhatt, Maya Armstrong, Tassy Parker et al. 4 citations

Post-traumatic stress disorder (PTSD), a common condition with potentially devastating individual, family, and societal consequences, is highly associated with substance use disorders (SUDs). The association between PTSD and SUD is complex and may involve adverse childhood experiences (ACEs), historical and multi-generational traumas, and social determinants of health as well as cultural and...

DOI: 10.3389/fphar.2022.905753 (opens in new tab) Psychosocial Indigenous Psychological intervention Population +4

Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca

Frontiers in Pharmacology May 2, 2022 Ilana Berlowitz, Klemens Egger, Paul Cumming 32 citations

The monoamine oxidases (MAOs) are flavin-containing amine oxidoreductases responsible for metabolism of many biogenic amine molecules in the brain and peripheral tissues. Whereas serotonin is the preferred substrate of MAO-A, phenylethylamine is metabolized by MAO-B, and dopamine and tyramine are nearly ambivalent with respect to the two isozymes. β-Carboline alkaloids such as harmine,...

DOI: 10.3389/fphar.2022.886408 (opens in new tab) Ayahuasca Serotonin Pharmacology Monoamine neurotransmitter +10

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Frontiers in Pharmacology March 31, 2022 Roberta Murphy, Roberta Murphy, Hannes Kettner et al. 229 citations

Background: Across psychotherapeutic frameworks, the strength of the therapeutic alliance has been found to correlate with treatment outcomes; however, its role has never been formally assessed in a trial of psychedelic-assisted therapy. We aimed to investigate the relationships between therapeutic alliance and rapport, the quality of the acute psychedelic experience and treatment outcomes....

DOI: 10.3389/fphar.2021.788155 (opens in new tab) Mystical experience Therapeutic relationship Emotional breakthrough Psilocybin therapy: psilocybin +4

Language as a Window Into the Altered State of Consciousness Elicited by Psychedelic Drugs

Frontiers in Pharmacology March 22, 2022 Enzo Tagliazucchi 20 citations

Psychedelics are drugs capable of eliciting profound alterations in the subjective experience of the users, sometimes with long-lasting consequences. Because of this, psychedelic research tends to focus on human subjects, given their capacity to construct detailed narratives about the contents of their consciousness experiences. In spite of its relevance, the interaction between serotonergic...

DOI: 10.3389/fphar.2022.812227 (opens in new tab) Psilocybin Consciousness Neurochemical Relevance law +8

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report

Frontiers in Pharmacology March 9, 2022 Drummond E-Wen Mcculloch, Maria Zofia Grzywacz, Martin Bruun Madsen et al. 91 citations

Psychedelic drugs such as psilocybin have shown substantial promise for the treatment of several psychiatric conditions including mood and addictive disorders. They also have the remarkable property of producing persisting positive psychological changes in healthy volunteers for at least several months. In this study (NCT03289949), 35 medium-high doses of psilocybin were administered to 28...

DOI: 10.3389/fphar.2022.841648 (opens in new tab) Psilocybin Mood Hallucinogen Clinical psychology +1

Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines

Frontiers in Pharmacology February 9, 2022 Karolina E. Kolaczynska, Dino Luethi, Dino Luethi et al. 16 citations

3,4,5-Trimethoxyphenethylamine (mescaline) is a psychedelic alkaloid found in peyote cactus. Related 4-alkoxy-3,5-dimethoxy-substituted phenethylamines (scalines) and amphetamines (3C-scalines) are reported to induce similarly potent psychedelic effects and are therefore potential novel therapeutics for psychedelic-assisted therapy. Herein, several pharmacologically uninvestigated scalines and...

Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder

Frontiers in Pharmacology January 27, 2022 Athanasios Markopoulos, Antonio Inserra, Danilo de Gregorio et al. 44 citations

Recent clinical and preclinical evidence points towards empathogenic and prosocial effects elicited by psychedelic compounds, notably the serotonin 5-HT 2A agonists lysergic acid diethylamide (LSD), psilocybin, N,N-Dimethyltryptamine (DMT), and their derivatives. These findings suggest a therapeutic potential of psychedelic compounds for some of the behavioural traits associated with autism...

Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study.

Frontiers in Pharmacology 2022 Daniel Perkins, Broc A. Pagni, Jerome Sarris et al. 53 citations

Background: Naturalistic and placebo-controlled studies suggest ayahuasca, a potent psychedelic beverage originating from Indigenous Amazonian tradition, may improve mental health, alter personality structure, and reduce alcohol and drug intake. To better understand ayahuasca's therapeutic potential and to identify factors that influence therapeutic efficacy, we conducted a naturalistic,...

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.

Frontiers in Pharmacology 2022 Margarida L F Martins, Paniz Heydari, Wenlong Li et al. 9 citations

The psychedelic alkaloid ibogaine is increasingly used as an oral treatment for substance use disorders, despite being unlicensed in most countries and having reported adverse events. Using wild-type and genetically modified mice, we investigated the impact of mouse (m)Abcb1a/1b and Abcg2 drug efflux transporters, human and mouse OATP drug uptake transporters, and the CYP3A drug-metabolizing...

Sex Differences in Kappa Opioid Receptor Agonist Mediated Attenuation of Chemotherapy-Induced Neuropathic Pain in Mice.

Frontiers in Pharmacology 2022 Kelly F Paton, Dan Luo, Anne C. la Flamme et al.

Chemotherapy-induced neuropathic pain is a common side effect for cancer patients which has limited effective treatment options. Kappa opioid receptor (KOR) agonists are a promising alternative to currently available opioid drugs due to their low abuse potential. In the current study, we have investigated the effects of Salvinorin A (SalA) analogues, 16-Ethynyl SalA, 16-Bromo SalA and...

DOI: 10.3389/fphar.2022.813562 (opens in new tab) Full text (opens in new tab) Salvinorin a Chemotherapy-induced neuropathic pain Kappa opioid receptor Paclitaxel +1

Agonist-Promoted Phosphorylation and Internalization of the Kappa Opioid Receptor in Mouse Brains: Lack of Connection With Conditioned Place Aversion.

Frontiers in Pharmacology 2022 Chongguang Chen, Peng Huang, Kathryn Bland et al.

Selective kappa opioid receptor (KOR) agonists are promising antipruritic agents and analgesics. However, clinical development of KOR agonists has been limited by side effects, including psychotomimetic effects, dysphoria, and sedation, except for nalfurafine, and recently. CR845 (difelikefalin). Activation of KOR elicits G protein- and β-arrestin-mediated signaling. KOR-induced analgesic and...

DOI: 10.3389/fphar.2022.835809 (opens in new tab) Full text (opens in new tab) Analgesic effect Antipruritic effect Conditioned place aversion Kappa opioid receptor +4

Mechanisms of the Rapid Effects of Ketamine on Depression and Sleep Disturbances: A Narrative Review

Frontiers in Pharmacology December 14, 2021 Bijia Song, Junchao Zhu

Recently, sleep has been recognized as a crucial factor for health and longevity. The daily sleep/wake cycle provides the basis of biorhythm, which controls whole-body homeostasis and homeodynamics. Sleep disturbances can contribute to several physical and psychological disorders, including cardiovascular disease, obesity, depression, and cognitive dysfunction. The clinical use of the...

CBD Effects on Motor Profile and Neurobiological Indices Related to Glutamatergic Function Induced by Repeated Ketamine Pre-Administration

Frontiers in Pharmacology October 27, 2021 Nafsika Poulia, Foteini Delis, Charalampos Brakatselos et al.

Clinical evidence and experimental studies have shown the psychotomimetic properties induced by ketamine. Moreover, acute or chronic ketamine (KET) administration has been widely used for modeling schizophrenia-like symptomatology and pathophysiology. Several studies have reported the antipsychotic potential of cannabidiol (CBD), while there is limited information on the cannabidiol effect on...

Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being

Frontiers in Pharmacology October 1, 2021 Maggie Kiraga, Natasha L. Mason, Malin V. Uthaug et al. 83 citations

Background: Naturalistic and placebo-controlled studies have suggested that ayahuasca, a traditional Amazonian beverage, could be helpful in the treatment of psychopathologies like depression and anxiety disorders by changing otherwise disturbed cognitive and emotional processes. To better understand its full therapeutic potential, one way is to study the effects on processes like flexible...

The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies

Frontiers in Pharmacology September 29, 2021 João Castelhano, Gisela Lima, Marta Teixeira et al. 34 citations

There is an increasing interest in the neural effects of psychoactive drugs, in particular tryptamine psychedelics, which has been incremented by the proposal that they have potential therapeutic benefits, based on their molecular mimicry of serotonin. It is widely believed that they act mainly through 5HT2A receptors but their effects on neural activation of distinct brain systems are not...

Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis

Frontiers in Pharmacology September 16, 2021 Lukas A Basedow, Thomas Riemer, Simon Reiche et al. 16 citations

Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at 5-HT 2a receptors. Besides the ability of these substances to facilitate profoundly altered states of consciousness, persisting psychological effects have been reported after single administrations, which outlast the acute psychedelic effects. In...

Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences

Frontiers in Pharmacology August 27, 2021 Giulia Costa, Francesca Felicia Caputi, Marcello Serra et al.

3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) is an amphetamine-related drug that may damage the dopaminergic nigrostriatal system. To investigate the mechanisms that sustain this toxic effect and ascertain their sex-dependence, we evaluated in the nigrostriatal system of MDMA-treated (4 × 20 mg/kg, 2 h apart) male and female mice the activity of superoxide dismutase (SOD), the gene...

Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin

Frontiers in Pharmacology July 13, 2021 Friederike Holze, Isidora Avedisian, Nimmy Varghese et al. 66 citations

The psychedelic lysergic acid diethylamide (LSD) has experienced a revival in research, including clinical trials that evaluate LSD-assisted psychotherapy. LSD induces perceptual alterations and influences emotion processing in ways that may support psychotherapy. Here, we investigated the effects of LSD on emotional empathy and mediating role of the serotonin 5-hydroxytryptamine-2A (5-HT 2A )...

Amazonian Medicine and the Psychedelic Revival: Considering the “Dieta”

Frontiers in Pharmacology May 28, 2021 David M. O’shaughnessy, Ilana Berlowitz 21 citations

Background: In Peruvian Amazonian medicine, plant diets ( dietas ) are a fundamental and highly flexible technique with a variety of uses: from treating and preventing illness, to increasing strength and resilience, to rites of passage, to learning even medicine itself. Many of the plants used in diets are psychoactive; for example, one now well-known plant that can be dieted is Banisteriopsis...

DOI: 10.3389/fphar.2021.639124 (opens in new tab) Ayahuasca Amazonian Context archaeology Traditional medicine +6